Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Tamoxifen
Sponsor: Oana Danciu, MD
Collaborators: Pfizer|Big Ten Cancer Research Consortium